Compare Starbucks Corp (SBUX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Tango Therapeutics Inc. — how do they compare? Starbucks Corp trades at $93.46 (market cap $104.88B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Starbucks Corp is far larger — about 28× Tango Therapeutics Inc.'s market cap, and Starbucks Corp pays a 2.74% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and Tango Therapeutics Inc. for 0 Days on average.
| SBUX | TNGX | |
|---|---|---|
Market Cap | $104.88B | $3.75B |
Volume | 9,749,448 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $32.90 |
52-Week Low | $79.60 | $7.50 |
Typical Hold Time | 190 Days | 0 Days |
Enterprise Value | $123.70B | $2.77B |
Dividend Yield | 2.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBUX trades at $93.25, up 1.05% on the day, amid a bearish technical signal and mixed fundamentals. Recent earnings show beats in Q1 and Q2 2026 but a miss in Q4 2025, with net income margin at 5.17%. The company is undergoing a strategic reset, closing 250 North American stores to optimize its portfolio, while facing headwinds from labor relations and geopolitical pressures in China.
The stock presents a cautious outlook with a high P/E of 53.18 suggesting premium valuation, yet analyst consensus targets $115.50 imply upside. Key risks include execution of store closures, competitive pressures, and macroeconomic sensitivity. Investor sentiment is divided, balancing restructuring potential against near-term operational challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
